CRM1, an RNA transporter, is a major species-specific restriction factor of human T cell leukemia virus type 1 (HTLV-1) in rat cells

Microbes and Infection
Xianfeng ZhangHisatoshi Shida

Abstract

Rat ortholog of human CRM1 has been found to be responsible for the poor activity of viral Rex protein, which is essential for RNA export of human T cell leukemia virus type 1 (HTLV-1). Here, we examined the species-specific barrier of HTLV-1 by establishing rat cell lines, including both adherent and CD4(+) T cells, which express human CRM1 at physiological levels. We demonstrated that expression of human CRM1 in rat cells is not harmful to cell growth and is sufficient to restore the synthesis of the viral structural proteins, Gag and Env, at levels similar to those in human cells. Gag precursor proteins were efficiently processed to the mature forms in rat cells and released into the culture medium as sedimentable viral particles. An HTLV-1 pseudovirus infection system suggested that the released virus particles are fully infectious. Our newly developed reporter cell system revealed that Env proteins produced in rat cells are fully fusogenic, which is the basis for cell-cell HTLV-1 infection. Moreover, we show that the early steps in infection, from post-entry uncoating to integration into the host chromosomes, occur efficiently in rat cells. These results, in conjunction with reports describing efficient entry of HTLV-1 int...Continue Reading

References

Nov 11, 1991·International Journal of Cancer. Journal International Du Cancer·T SugaK Uchida
Jan 1, 1991·Annual Review of Microbiology·B R Cullen
Jul 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·H P BogerdW C Greene
May 3, 1986·Lancet·M OsameM Tara
Apr 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·J FujisawaM Yoshida
Jun 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·J InoueM Seiki
Sep 15, 1983·International Journal of Cancer. Journal International Du Cancer·K NagyR A Weiss
Oct 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·Y HinumaI Miyoshi
Aug 1, 1994·International Journal of Cancer. Journal International Du Cancer·F IbrahimR Bomford
Mar 13, 2001·Annual Review of Immunology·M Yoshida
May 11, 2001·Japanese Journal of Cancer Research : Gann·R FengM Miwa
Apr 5, 2002·The Journal of Biological Chemistry·Michael E NemergutIan G Macara
Aug 1, 2002·Japanese Journal of Cancer Research : Gann·Binlian SunMasanao Miwa
Nov 19, 2003·Cell·Nicolas ManelJean-Luc Battini
May 26, 2004·AIDS Research and Human Retroviruses·Therese M McGinnPatricia N Fultz

❮ Previous
Next ❯

Citations

Jul 15, 2009·Microbes and Infection·Ryo TakayanagiHisatoshi Shida
Jan 22, 2011·Genes to Cells : Devoted to Molecular & Cellular Mechanisms·Mika Nagai-FukatakiHisatoshi Shida
Oct 8, 2016·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Fang ZhouLu Yue
Mar 23, 2017·Genes to Cells : Devoted to Molecular & Cellular Mechanisms·Hisatoshi ShidaYoshio Hayashi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.